UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 18, 2004
BrainStorm Cell Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Washington 333-61610 912061053
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
36 Derech Bait Lechem
Jerusalem, Israel 77002
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 011-972-2-6737445
Golden Hand Resources, Inc.
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal
Year
On November 15, 2004, our board of directors authorized an amendment to our
Articles of Incorporation to change the name of our Company from "Golden Hand
Resources Inc." to "BrainStorm Cell Therapeutics Inc." We are changing the name
of the Company to better reflect our business objectives going forward in the
stem cell research arena. On November 18, 2004, we filed such amended Articles
of Incorporation with the State of Washington and we have requested from the OTC
Bulletin Board that our trading symbol be changed as well to reflect our new
name. We expect to begin trading under our new symbol (BCLI.OB) beginning
November 24, 2004. A copy of the Articles of Amendment to our Articles of
Incorporation reflecting this change is attached hereto as Exhibit 3.i.01. A
copy of a press release regarding this announcement is attached as Exhibit 99.1
hereto.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits.
3.i.01 Articles of Amendment to Articles of Incorporation
99.1 Press Release dated November 23, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: November 22, 2004
BRAINSTORM CELL THERAPEUTICS INC.
/s/ Yaffa Beck
----------------------------
Name: Yaffa Beck
Title: President & CEO
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
3.i.01 Articles of Amendment to Articles of Incorporation
99.1 Press Release dated November 23, 2004